Search Results

Case Study: Immunogenicity of Natalizumab.

• Authors : Van De Weert, Marco; Møller, Eva Horn; Subramanyam, Meena

• Source: Immunogenicity of Biopharmaceuticals; 2008, p173-187, 15p

Record details

Natalizumab.

• Authors : Tridente, Giuseppe

• Source: Adverse Events with Biomedicines; 2014, p267-275, 9p

Record details

Natalizumab, infusion

• Source: RelayClinical Education. February, 2012, Vol. 2012 Issue 1

Record details

Natalizumab (Tysabri).

• Authors : Dübel, Stefan

• Source: Handbook of Therapeutic Antibodies; 2007, p941-950, 10p

Record details

Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®).

• Source: Handbook of Therapeutic Antibodies (9783527329373); 2014, p2087-2112, 26p

Record details

Progressive multifokale Leukoenzephalopathie unter Therapie mit Natalizumab.

• Authors : Faiss, J. H.

• Source: Komplikationen in der Neurologie; 2016, p185-196, 12p

Record details

Omalizumab (Xolair): Anti-Immunoglobulin E Treatment in Allergic Diseases.

• Authors : Dübel, Stefan

• Source: Handbook of Therapeutic Antibodies; 2007, p951-997, 47p

Record details

Emerging Technologies for Antibody Selection.

• Authors : Dübel, Stefan

• Source: Handbook of Therapeutic Antibodies; 2007, p431-443, 13p

Record details

Selection Strategies III: Transgenic Mice.

• Authors : Dübel, Stefan

• Source: Handbook of Therapeutic Antibodies; 2007, p69-93, 25p

Record details

Emerging Therapeutic Concepts I: ADEPT.

• Authors : Dübel, Stefan

• Source: Handbook of Therapeutic Antibodies; 2007, p501-513, 13p

Record details